Abstract
MUC1 mucin is known to serve as a target molecule in the killing of breast cancer cells by cytotoxic T-lymphocytes (CTLs). We searched for a possible mechanism allowing tumour cells to escape from autologous CTLs. When the killing of breast cancer cells by autologous lymphocytes was examined in 26 patients with breast cancer, significant tumour cell lysis was observed in 8 patients, whereas virtually no autologous tumour cell lysis was detected in as many as 18 patients. In the patients who showed negligible tumour cell lysis, the autologous tumour cells expressed MUC1-related antigenic epitopes much more weakly than the tumour cells in the patients who exhibited strong cytotoxicity (significant statistically at P< 0.0005–0.0045), suggesting that the unresponsiveness of cancer cells to CTLs observed in these patients was mainly due to loss of MUC1 expression or modulation of its antigenicity. A breast cancer cell line, NZK-1, established from one of the cytotoxicity-negative patients, did not express MUC1 and was resistant to killing by CTLs, while control breast cancer cell lines expressing MUC-1 were readily killed by CTLs. Transfection of NZK-1 cells with MUC1 cDNA induced significant lysis by autologous T-lymphocytes. These results supported the importance of MUC1 mucin in autologous anti-tumour immunity, but suggested that the major escape mechanism of tumour cells from autologous T-lymphocytes is the loss and/or modulation of MUC1 antigenicity on tumour cells, which would limit the effectiveness of possible immunotherapy designed to target the MUC1 mucin. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Acres B, Apostolopoulos V, Balloul JM, Wreschner D, Xing PX, Ali-Hadji D, Bizouarne N, Kieny MP and McKenzie IFC (2000) MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines. Cancer Immunol Immunother 48: 588–594
Agrawal B, Reddish MA and Longenecker BM (1996) In vitro induction of MUC-1 peptide-specific type 1 T lymphocyte and cytotoxic T lymphocyte responses from healthy multiparous donors. J Immunol 157: 2089–2095
Akagi J, Hodge JW, McLaughlin JP, Gritz L, Mazzara G, Kufe D, Schlom J and Kantor JA (1997) Therapeutic antitumor response after immunization with an admixture of recombinant vaccinia viruses expressing a modified MUC1 gene and the murine T-cell costimulatory molecule B7. J Immunother 20: 38–47
Bara J, Imberty A, Perez S, Imai K, Yachi A and Oriol R (1993) A fucose residue can mask the MUC-1 epitopes in normal and cancerous gastric mucosae. Int J Cancer 54: 607–613
Barnd DL, Lan MS, Metzgar RS and Finn OJ (1989) Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc Natl Acad Sci USA 86: 7159–7163
Blockzjil A, Nilsson K and Nilsson O (1998) Epitope characterization of MUC1 antibodies. Tumor Biol 19: 46–56
Böhm CM, Mulder MC, Zennadi R, Notter M, Schmitt-Gräff A, Finn OJ, Taylor-Papadimitriou J, Stein H, Clausen H, Riecken EO and Hanski C (1997) Carbohydrate recognition on MUC1-expressing targets enhances cytotoxicity of a T cell subpopulation. Scand J Immunol 46: 27–34
Burchell J, Wang D and Taylor-Papadimitriou J (1984) Detection of the tumour-associated antigens recognized by the monoclonal antibodies HMFG-1 and 2 in serum from patients with breast cancer. Int J Cancer 34: 763–768
Burchell J, Gendler S, Taylor-Papadimitriou J, Girling A, Lewis A, Millis R and Lamport D (1987) Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res 47: 5476–5482
Carmon L, El-Shami KM, Paz A, Pascolo S, Tzehoval E, Tirosh B, Koren R, Feldman M, Fridkin M, Lemonnier FA and Eisenbach L (2000) Novel breast-tumor-associated MUC1-derived peptides: Characterization in Db-/-x β2 microglobulin (β2m) null mice transgenic for a chimeric HLA-A2.1/Db-β2 microglobulin single chain. Int J Cancer 85: 391–397
Dai J, Allard WJ, Davis G and Yeung KK (1998) Effect of desialylation on binding, affinity, and specificity of 56 monoclonal antibodies against MUC1 mucin. Tumor Biol 19: 100–110
Devine PL, McGuckin MA, Ramm LE, Ward BG, Pee D and Long S (1993) Serum mucin antigens CASA and MSA in tumors of the breast, ovary, lung, pancreas, bladder, colon, and prostate. A blind trial with 420 patients. Cancer 72: 2007–2015
Finke JH, Rayman P, Alexander J, Edinger M, Tubbs RR, Connelly R, Pontes E and Bukowski R (1990) Characterization of the cytolytic activity of CD4+and CD8+tumor-infiltrating lymphocytes in human renal cell carcinoma. Cancer Res 50: 2363–2370
Gendler S, Taylor-Papadimitriou J, Duhig T, Rothbard J and Burchell J (1988) A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J Biol Chem 263: 12820–12823
Gendler SJ, Lancaster CA, Taylor J, Duhig T, Peat N, Burchell J, Pemberton L, Lalani E and Wilson D (1990) Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J Biol Chem 265: 15286–15293
Gong JL, Chen DS, Kashiwaba M, Li YQ, Chen L, Takeuchi H, Qu H, Rowse GJ, Gendler SJ and Kufe D (1998) Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc Natl Acad Sci USA 95: 6279–6283
Hakomori S (1996) Tumor malignancy defined by aberrant glycosylation and sphingo (glyco)lipid metabolism. Cancer Res 56: 5309–5318
Hanisch FG, Uhlenbruck G, Peter Katalinic J, Egge H, Dabrowski J and Dabrowski U (1989) Structures of neutral O-linked polylactosaminoglycans on human skim milk mucins. A novel type of lineraly extended poly-N-acetyllactosamine backbones with Gal β(1–4)GlcNAc β(1–6) repeating units. J Biol Chem 264: 872–883
Ho SB, Shekels LL, Toribara NW, Kim YS, Lyftogt C, Cherwitz DL and Niehans GA (1995) Mucin gene expression in normal, preneoplastic, and neoplastic human gastric epithelium. Cancer Res 55: 2681–2690
Jerome KR, Domenech N and Finn OJ (1993) Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA. J Immunol 151: 1654–1662
Jerome KR, Kirk AD, Pecher G, Ferguson WW and Finn OJ (1997) A survivor of breast cancer with immunity to MUC-1 mucin, and lactational mastitis. Cancer Immunol Immunother 43: 355–360
Karanikas V, Hwang LA, Pearson J, Ong CS, Apostolopoulos V, Vaughan H, Xing PX, Jamieson G, Pietersz G, Tait B, Broadbent R, Thynne G and McKenzie IFC (1997) Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J Clin Invest 100: 2783–2792
Kontani K, Taguchi O, Narita T, Hiraiwa N, Sawai S, Hanaoka J, Ichinose M, Tezuka N, Inoue S, Fujino S and Kannagi R (2000) Autologous dendritic cells or cells expressing both B7–1 and MUC1 can rescue tumor-specific cytotoxic T lymphocytes from MUC1-mediated apoptotic cell death. J Leukocyte Biol 68: 225–232
Kotera Y, Fontenot JD, Pecher G, Metzgar RS and Finn OJ (1994) Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res 54: 2856–2860
Lan MS, Hollingsworth MA and Metzgar RS (1990) Polypeptide core of a human pancreatic tumor mucin antigen. Cancer Res 50: 2997–3001
Lloyd KO, Burchell J, Kudryashov V, Yin BWT and Taylor-Papadimitriou J (1996) Comparison of O -linked carbohydrate chains in MUC-1 mucin from normal breast epithelial cell lines and breast carcinoma cell lines – Demonstration of simpler and fewer glycan chains in tumor cells. J Biol Chem 271: 33325–33334
Magarian-Blander J, Hughey RP, Kinlough C, Poland PA and Finn OJ (1996) Differential expression of MUC1 on transfected cell lines influences its recognition by MUC1 specific T cells. Glycoconjugate J 13: 749–756
Magarian-Blander J, Ciborowski P, Hsia S, Watkins SC and Finn OJ (1998) Intercellular and intracellular events following the MHC-unrestricted TCR recognition of a tumor-specific peptide epitope on the epithelial antigen MUC1. J Immunol 160: 3111–3120
Ogata S, Uehara H, Chen A and Itzkowitz SH (1992) Mucin gene expression in colonic tissues and cell lines. Cancer Res 52: 5971–5978
Pecher G and Finn OJ (1996) Induction of cellular immunity in chimpanzees to human tumor-associated antigen mucin by vaccination with MUC-1 cDNA-transfected Epstein-Barr virus immortalized autologous B cells. Proc Natl Acad Sci USA 93: 1699–1704
Potter H, Weir L and Leder P (1984) Enhancer-dependent expression of human κ immunoglobulin genes introduced into mouse pre-B lymphocytes by electroporation. Proc Natl Acad Sci USA 81: 7161–7165
Price MR, Rye PD, Petrakou E, Murray A, Brady K, Imai S, Haga S, Kiyozuka Y, Schol D, Meulenbroek MF, Snijdewint FG, von Mensdorff-Pouilly S, Verstraeten RA, Kenemans P, Blockzjil A, Nilsson O, Reddish M, Suresh MR, Koganty RR, Fortier S, Baronic L, Berg A, Longenecker MB and Hilgers J (1998) Summary report on the ISOBM TD-4 Workshop: Analysis of 56 monoclonal antibodies against the MUC1 mucin. San Diego, Calif., November 17–23, 1996. Tumor Biol 19: 1–20
Rowse GJ, Tempero RM, VanLith ML, Hollingsworth MA and Gendler SJ (1998) Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model. Cancer Res 58: 315–321
Samuel J, Budzynski WA, Reddish MA, Ding L, Zimmermann GL, Krantz MJ, Koganty RR and Longenecker BM (1998) Immunogenicity and antitumor activity of a liposomal MUC1 peptide-based vaccine. Int J Cancer 75: 295–302
Siddiqui J, Abe M, Hayes D, Shani E, Yunis E and Kufe D (1988) Isolation and sequencing of a cDNA coding for the human DF3 breast carcinoma-associated antigen. Proc Natl Acad Sci USA 85: 2320–2323
Smyth MJ and Ortaldo JR (1993) Mechanisms of cytotoxicity used by human peripheral blood CD4+and CD8+T cell subsets. The role of granule exocytosis. J Immunol 151: 740–747
Swallow DM, Gendler S, Griffiths B, Corney G, Taylor-Papadimitrious J and Bramwell ME (1987) The human tumour-associated epithelial mucins are coded by an expressed hypervariable gene locus PUM. Nature 328: 82–84
Takada A, Ohmori K, Yoneda T, Tsuyuoka K, Hasegawa A, Kiso M and Kannagi R (1993) Contribution of carbohydrate antigens sialyl Lewis A and sialyl Lewis X to adhesion of human cancer cells to vascular endothelium. Cancer Res 53: 354–361
Taylor-Papadimitriou J and Finn OJ (1997) Biology, biochemistry and immunology of carcinoma-associated mucins. Immunol Today 18: 105–107
von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P, Snijdewint FGM, Kok A, Van Kamp GJ, Paul MA, Van Diest PJ, Meijer S and Hilgers J (2000) Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J Clin Oncol 18: 574–583
Willsher PC, Xing P-X, Clark CP, Ho DWM and McKenzie IFC (1993) Mucin 1 antigens in the serum and bronchial lavage fluid of patients with lung cancer. Cancer 72: 2936–2942
Wright SE, Kilinski G, Talib G, Lowe KE, Burnside JS, Wu JY, Dolby N, Dombrowski KE, Lebkowski JS and Philip R (2000) Cytotoxic T lymphocytes from humans with adenocarcinomas stimulated by native MUC1 mucin and a mucin peptide mutated at a glycosylation site. J Immunother 23: 2–10
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Kontani, K., Taguchi, O., Narita, T. et al. Modulation of MUC1 mucin as an escape mechanism of breast cancer cells from autologous cytotoxic T-lymphocytes. Br J Cancer 84, 1258–1264 (2001). https://doi.org/10.1054/bjoc.2000.1744
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1744
Keywords
This article is cited by
-
Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential?
Journal for ImmunoTherapy of Cancer (2019)
-
MUC-1 gene is associated with prostate cancer death: a 20-year follow-up of a population-based study in Sweden
British Journal of Cancer (2007)
-
Vaccine therapy in non—small-cell lung cancer
Current Oncology Reports (2007)